Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™-DEN2) vaccine:: Phase I clinical trial for safety and immunogenicity

被引:159
作者
Guirakhoo, Farshad
Kitchener, Scott
Morrison, Dennis
Forrat, Remi
McCarthy, Karen
Nichols, Richard
Yoksan, Sutee
Duan, Xiaochu
Ermak, Thomas H.
Kanesa-Thasan, Niranjian
Bedford, Philip
Lang, Jean
Quentin-Millet, Marie-Jose
Monath, Thomas P.
机构
[1] Acambis Inc, Cambridge, MA 02139 USA
[2] Acambis Res Ltd, Cambridge, England
[3] Sanofi Pasteur, Marcy Letoile, France
[4] Mahidol Univ, Ctr Vaccine Dev, Inst Sci & Technol Res & Dev, Nakhon Pathom, Thailand
来源
HUMAN VACCINES | 2006年 / 2卷 / 02期
关键词
live attenuated; chimeric yellow fever-dengue 2; Phase I trial; safety; immunogenicity;
D O I
10.4161/hv.2.2.2555
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A randomized double-blind Phase I Trial was conducted to evaluate safety, tolerability, and immunogenicity of a yellow fever (YF)-dengue 2 (DEN2) chimera (ChimeriVax(TM)DEN2) in comparison to that of YF vaccine (YF-VAX(R)). Forty-two healthy YF naive adults randomly received a single dose of either ChimeriVax(TM)-DEN2 (high dose, 5 log plaque forming units [PFU] or low dose, 3 log PFU) or YF-VAX(R) by the subcutaneous route (SC). To determine the effect of YF preimmunity on the ChimeriVax(TM)-DEN2 vaccine, 14 subjects previously vaccinated against YF received a high dose of ChimeriVax(TM)-DEN2 as an open-label vaccine. Most adverse events were similar to YF-VAX(R) and of mild to moderate intensity, with no serious side-effects. One hundred percent and 92.3% of YF naive subjects inoculated with 5.0 and 3.0 log(10) PFU of ChimeriVax(TM)-DEN2, respectively, seroconverted to wt DEN2 (strain 1668 1); 92% of subjects inoculated with YF-VAX(R) seroconverted to YF 17D virus but none of YF naive subjects inoculated with ChimeriVax-DEN2 seroconverted to YF 17D virus. Low seroconversion rates to heterologous DEN serotypes 1, 3 and 4 were observed in YF naive subjects inoculated with either ChimeriVax(TM)-DEN2 or YF-VAX(R). In contrast, 100% of YF immune subjects inoculated with ChimeriVax(TM)-DEN2 seroconverted to all 4 DEN serotypes. Surprisingly, levels of neutralizing antibodies to DEN 1, 2 and 3 viruses in YF immune subjects persisted after 1 year. These data demonstrated that (1) the safety and immunogenicity profile of the ChimeriVax(TM)-DEN2 vaccine is consistent with that of YF-VAX(R), and (2) preimmunity to YF virus does not interfere with ChimeriVax(TM)-DEN2 immunization, but induces a long lasting and cross neutralizing antibody response to all 4 DEN serotypes. The latter observation can have practical implications toward development of a dengue vaccine.
引用
收藏
页码:60 / 67
页数:8
相关论文
共 36 条
[1]   2 EPISODES OF DENGUE FEVER CAUSED BY TYPES 4 AND 1 VIRUSES IN AN INDIVIDUAL PREVIOUSLY IMMUNIZED AGAINST YELLOW FEVER [J].
CAREY, DE ;
MYERS, RM ;
RODRIGUES, FM .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1965, 14 (03) :448-+
[2]   Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting [J].
Chambers, TJ ;
Tsai, TF ;
Pervikov, Y ;
Monath, TP .
VACCINE, 1997, 15 (14) :1494-1502
[3]  
ECKELS KH, 1985, J IMMUNOL, V135, P4201
[4]  
Gubler DJ, 2014, DENGUE AND DENGUE HEMORRHAGIC FEVER, 2ND EDITION, P1, DOI 10.1079/9781845939649.0001
[5]   Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates [J].
Guirakhoo, F ;
Weltzin, R ;
Chambers, TJ ;
Zhang, ZX ;
Soike, K ;
Ratterree, M ;
Arroyo, J ;
Georgakopoulos, K ;
Catalan, J ;
Monath, TP .
JOURNAL OF VIROLOGY, 2000, 74 (12) :5477-5485
[6]   Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates [J].
Guirakhoo, F ;
Pugachev, K ;
Zhang, Z ;
Myers, G ;
Levenbook, I ;
Draper, K ;
Lang, J ;
Ocran, S ;
Mitchell, F ;
Parsons, M ;
Brown, N ;
Brandler, S ;
Fournier, C ;
Barrere, B ;
Rizvi, F ;
Travassos, A ;
Nichols, R ;
Trent, D ;
Monath, T .
JOURNAL OF VIROLOGY, 2004, 78 (09) :4761-4775
[7]   Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates [J].
Guirakhoo, F ;
Pugachev, K ;
Arroyo, J ;
Miller, C ;
Zhang, ZX ;
Weltzin, R ;
Georgakopoulos, K ;
Catalan, J ;
Ocran, S ;
Draper, K ;
Monath, TP .
VIROLOGY, 2002, 298 (01) :146-159
[8]   Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine [J].
Guirakhoo, F ;
Arroyo, J ;
Pugachev, KV ;
Miller, C ;
Zhang, ZX ;
Weltzin, R ;
Georgakopoulos, K ;
Catalan, J ;
Ocran, S ;
Soike, K ;
Ratterree, M ;
Monath, TP .
JOURNAL OF VIROLOGY, 2001, 75 (16) :7290-7304
[9]   EPITOPE MODEL OF TICK-BORNE ENCEPHALITIS-VIRUS ENVELOPE GLYCOPROTEIN-E - ANALYSIS OF STRUCTURAL-PROPERTIES, ROLE OF CARBOHYDRATE SIDE-CHAIN, AND CONFORMATIONAL-CHANGES OCCURRING AT ACIDIC PH [J].
GUIRAKHOO, F ;
HEINZ, FX ;
KUNZ, C .
VIROLOGY, 1989, 169 (01) :90-99
[10]   West Nile virus inhibits the signal transduction pathway of alpha interferon [J].
Guo, JT ;
Hayashi, J ;
Seeger, C .
JOURNAL OF VIROLOGY, 2005, 79 (03) :1343-1350